Literature DB >> 15374291

The Italian version of the Alzheimer's Disease Assessment Scale (ADAS): psychometric and normative characteristics from a normal aged population.

M Fioravanti1, D Nacca, A E Buckley, E Ferrario, O Varetto, P Mogni, F Fabris.   

Abstract

The Alzheimer's Disease Assesment Scale (ADAS) was specifically proposed for the clinical assessment of patients suffering from dementia and is used in different countries. The Italian version of ADAS is presented in this paper together with the description of criteria used in transforming the American edition in the Italian edition. Psychometric and normative data are illustrated and discussed. A sample of 95 healthy volunteers of both sexes ranging in age from 50 to 79 years were recruited from the general population in different parts of Italy and from different social and educational levels. Their performance on the ADAS was analysed by sex, age, and educational level. Results indicated a specific influence of subjects' educational level on the Cognitive Subscale Total Score of ADAS and the need for an adequate correction was evidenced. The two objective measures of memory which constitute, together with the Cognitive Subscale Total Score, the cognitive subscale of ADAS were sensitive to both age and educational level, requiring corrections. The factor structure of the cognitive subscale of ADAS confirms the validity of distinguishing between the clinical-functional scores, which are summarized by the Cognitive Subscale Total Score (CSTS), from those of the objective memory tasks, which are kept separate and used to quantify specific memory characteristics. The main components of the CSTS were 3 factors. The first factor was

Entities:  

Year:  1994        PMID: 15374291     DOI: 10.1016/0167-4943(94)90022-1

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  7 in total

1.  Gradient impact of cognitive decline in unilateral vestibular hypofunction after rehabilitation: preliminary findings.

Authors:  Alessandro Micarelli; Andrea Viziano; Ernesto Bruno; Elisa Micarelli; Ivan Augimeri; Marco Alessandrini
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-29       Impact factor: 2.503

Review 2.  Psychometrics and diagnostics of Italian cognitive screening tests: a systematic review.

Authors:  Edoardo Nicolò Aiello; Sara Rimoldi; Nadia Bolognini; Ildebrando Appollonio; Giorgio Arcara
Journal:  Neurol Sci       Date:  2021-11-24       Impact factor: 3.830

3.  Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study.

Authors: 
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

4.  Use of neuropsychological tests for the diagnosis of dementia: a survey of Italian memory clinics.

Authors:  Alessandra Di Pucchio; Nicola Vanacore; Fabrizio Marzolini; Eleonora Lacorte; Teresa Di Fiandra; Marina Gasparini
Journal:  BMJ Open       Date:  2018-03-28       Impact factor: 2.692

5.  Health-Related Predictors of Changes in Cognitive Status in Community-Dwelling Older Individuals.

Authors:  Caterina Trevisan; Paola Siviero; Federica Limongi; Marianna Noale; Stefania Maggi
Journal:  Front Aging Neurosci       Date:  2022-06-20       Impact factor: 5.702

6.  Decreased Frontal Gamma Activity in Alzheimer Disease Patients.

Authors:  Elias P Casula; Maria C Pellicciari; Sonia Bonnì; Ilaria Borghi; Michele Maiella; Martina Assogna; Marilena Minei; Caterina Motta; Alessia D'Acunto; Francesco Porrazzini; Valentina Pezzopane; Lucia Mencarelli; Andrea Roncaioli; Lorenzo Rocchi; Danny A Spampinato; Carlo Caltagirone; Emiliano Santarnecchi; Alessandro Martorana; Giacomo Koch
Journal:  Ann Neurol       Date:  2022-07-07       Impact factor: 11.274

7.  Cognitive Assessment of Patients With Alzheimer's Disease by Telemedicine: Pilot Study.

Authors:  Anna Carotenuto; Raffaele Rea; Enea Traini; Giovanna Ricci; Angiola Maria Fasanaro; Francesco Amenta
Journal:  JMIR Ment Health       Date:  2018-05-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.